Age-related macular degeneration (AMD) is one of the leading causes of vision loss among older adults, affecting the part of the eye responsible for sharp, central vision. Tasks like reading, driving, recognizing faces, or even seeing details can become increasingly difficult as the disease progresses. While there have long been treatments available for wet AMD, options for dry AMD have historically been limited. That’s why many patients are interested in learning about MacuMira, an innovative therapy designed for people living with dry AMD.

What Is Age-Related Macular Degeneration?

AMD is a condition that affects the macula, the central part of the retina that allows you to see fine details. As the macula deteriorates, central vision becomes blurry or distorted, while peripheral vision is usually preserved.

There are two forms of AMD:

Dry AMD, which accounts for approximately 85-90% of cases and develops gradually as retinal cells deteriorate.

Wet AMD, a less common but more aggressive form caused by abnormal blood vessel growth beneath the retina.

Early stages of AMD may not cause noticeable symptoms, which is why regular comprehensive eye exams are so important, particularly for adults over 50.

What Is MacuMira?

MacuMira is a non-invasive treatment designed for people with dry AMD. Unlike injections, medications, or surgery, the therapy uses low-level microcurrent stimulation delivered through closed eyelids to stimulate retinal cells and support visual function. It is authorized by Health Canada for improving visual function in patients with dry AMD. The treatment is performed in-office, allowing patients to relax while wearing the device for approximately 30 minutes before returning to their normal daily activities.

How Does MacuMira Work?

MacuMira uses gentle electrical microcurrents that are designed to stimulate cells within the retina, particularly the retinal pigment epithelium (RPE). These cells play an important role in maintaining retinal health and supporting vision.

The technology aims to enhance cellular activity and energy production within these retinal cells, helping support visual function. Researchers continue to study the exact biological mechanisms, but the therapy represents a different approach from traditional management strategies that primarily focus on slowing disease progression.

Who Might Benefit?

MacuMira is intended for patients diagnosed with dry AMD, particularly those in the early to intermediate stages. Whether someone is a good candidate depends on their overall eye health, medical history, and the recommendation of their eye care professional.

Because every patient’s situation is unique, a comprehensive eye examination is essential before determining whether this treatment is appropriate.

How Does It Compare to Traditional Management?

For many years, management of dry AMD focused on strategies such as:

Regular monitoring

Healthy lifestyle changes

Smoking cessation

Nutritional support, including AREDS or AREDS2 supplements for appropriate patients

While these approaches may help reduce the risk of progression in certain individuals, they are generally intended to slow progression rather than improve vision that has already been lost.

MacuMira offers a different approach by using non-invasive microcurrent stimulation to improve visual function in appropriate patients, according to its clinical data and Health Canada authorization.

Why Early Detection Still Matters

Even with emerging technologies, early diagnosis remains one of the most important factors in managing AMD. Many people don’t notice symptoms until vision has already changed, making routine eye exams essential for detecting the condition in its earliest stages.

Your optometrist can monitor changes in your retina, discuss risk factors such as age, family history, and smoking, and recommend the most appropriate management plan for your individual needs.

Looking Ahead

Advances in eye care continue to provide new hope for people living with dry AMD. While MacuMira is not considered a cure for age-related macular degeneration, it represents an innovative treatment option that may help improve visual function for eligible patients.

If you have been diagnosed with dry AMD or are concerned about changes in your vision, visit us at Beyond Vision for a comprehensive eye exam. Our team can evaluate your eye health, answer your questions, and discuss whether treatments such as MacuMira may be an appropriate option for you.